Literature DB >> 28301858

Anti-nerve growth factor therapy increases spontaneous day/night activity in mice with orthopedic surgery-induced pain.

Lisa A Majuta1, Jean-Marc G Guedon1, Stefanie A T Mitchell1, Michael H Ossipov1, Patrick W Mantyh1,2.   

Abstract

Total knee arthroplasty (TKA) and total hip arthroplasty (THA) are 2 of the most common and successful surgical interventions to relieve osteoarthritis pain. Control of postoperative pain is critical for patients to fully participate in the required physical therapy which is the most influential factor in effective postoperative knee rehabilitation. Currently, opiates are a mainstay for managing postoperative orthopedic surgery pain including TKA or THA pain. Recently, issues including efficacy, dependence, overdose, and death from opiates have made clinicians and researchers more critical of use of opioids for treating nonmalignant skeletal pain. In the present report, a nonopiate therapy using a monoclonal antibody raised against nerve growth factor (anti-NGF) was assessed for its ability to increase the spontaneous activity of the operated knee joint in a mouse model of orthopedic surgery pain-induced by drilling and coring the trochlear groove of the mouse femur. Horizontal activity and velocity and vertical rearing were continually assessed over a 20 hours day/night period using automated activity boxes in an effort to reduce observer bias and capture night activity when the mice are most active. At days 1 and 3, after orthopedic surgery, there was a marked reduction in spontaneous activity and vertical rearing; anti-NGF significantly attenuated this decline. The present data suggest that anti-NGF improves limb use in a rodent model of joint/orthopedic surgery and as such anti-NGF may be useful in controlling pain after orthopedic surgeries such as TKA or THA.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28301858      PMCID: PMC5370196          DOI: 10.1097/j.pain.0000000000000799

Source DB:  PubMed          Journal:  Pain        ISSN: 0304-3959            Impact factor:   7.926


  79 in total

1.  Serious joint-related adverse events in randomized controlled trials of anti-nerve growth factor monoclonal antibodies.

Authors:  M C Hochberg
Journal:  Osteoarthritis Cartilage       Date:  2015-01       Impact factor: 6.576

2.  Factors influencing the postoperative range of motion in total knee arthroplasty.

Authors:  J Ryu; S Saito; K Yamamoto; S Sano
Journal:  Bull Hosp Jt Dis       Date:  1993

Review 3.  Bone cancer pain: from mechanism to therapy.

Authors:  Patrick W Mantyh
Journal:  Curr Opin Support Palliat Care       Date:  2014-06       Impact factor: 2.302

Review 4.  Are older adults with chronic musculoskeletal pain less active than older adults without pain? A systematic review and meta-analysis.

Authors:  Brendon Stubbs; Tarik T Binnekade; Andy Soundy; Pat Schofield; Ivan P J Huijnen; Laura H P Eggermont
Journal:  Pain Med       Date:  2013-06-06       Impact factor: 3.750

5.  Sustained blockade of neurotrophin receptors TrkA, TrkB and TrkC reduces non-malignant skeletal pain but not the maintenance of sensory and sympathetic nerve fibers.

Authors:  Joseph R Ghilardi; Katie T Freeman; Juan M Jimenez-Andrade; William G Mantyh; Aaron P Bloom; Karyn S Bouhana; David Trollinger; James Winkler; Patrice Lee; Steven W Andrews; Michael A Kuskowski; Patrick W Mantyh
Journal:  Bone       Date:  2010-09-18       Impact factor: 4.398

Review 6.  Recent progress in understanding molecular mechanisms of cartilage degeneration during osteoarthritis.

Authors:  Meina Wang; Jie Shen; Hongting Jin; Hee-Jeong Im; John Sandy; Di Chen
Journal:  Ann N Y Acad Sci       Date:  2011-12       Impact factor: 5.691

7.  Dose reduction of meloxicam in dogs with osteoarthritis-associated pain and impaired mobility.

Authors:  B G J Wernham; B Trumpatori; J Hash; J Lipsett; G Davidson; P Wackerow; A Thomson; B D X Lascelles
Journal:  J Vet Intern Med       Date:  2011-11-01       Impact factor: 3.333

8.  A blocking antibody to nerve growth factor attenuates skeletal pain induced by prostate tumor cells growing in bone.

Authors:  Kyle G Halvorson; Kazufumi Kubota; Molly A Sevcik; Theodore H Lindsay; Julio E Sotillo; Joseph R Ghilardi; Thomas J Rosol; Leila Boustany; David L Shelton; Patrick W Mantyh
Journal:  Cancer Res       Date:  2005-10-15       Impact factor: 12.701

9.  OARSI guidelines for the non-surgical management of knee osteoarthritis.

Authors:  T E McAlindon; R R Bannuru; M C Sullivan; N K Arden; F Berenbaum; S M Bierma-Zeinstra; G A Hawker; Y Henrotin; D J Hunter; H Kawaguchi; K Kwoh; S Lohmander; F Rannou; E M Roos; M Underwood
Journal:  Osteoarthritis Cartilage       Date:  2014-01-24       Impact factor: 6.576

10.  Global positioning system derived performance measures are responsive indicators of physical activity, disease and the success of clinical treatments in domestic dogs.

Authors:  Elizabeth A Bruno; James W Guthrie; Stephen A Ellwood; Richard J Mellanby; Dylan N Clements
Journal:  PLoS One       Date:  2015-02-18       Impact factor: 3.240

View more
  5 in total

Review 1.  Targeting neurotrophic factors: Novel approaches to musculoskeletal pain.

Authors:  Anne-Marie Malfait; Rachel E Miller; Joel A Block
Journal:  Pharmacol Ther       Date:  2020-04-18       Impact factor: 12.310

2.  Anti-nerve growth factor does not change physical activity in normal young or aging mice but does increase activity in mice with skeletal pain.

Authors:  Lisa A Majuta; Stefanie A T Mitchell; Michael A Kuskowski; Patrick W Mantyh
Journal:  Pain       Date:  2018-11       Impact factor: 7.926

3.  Noninvasive Mechanical Joint Loading as an Alternative Model for Osteoarthritic Pain.

Authors:  Freija Ter Heegde; Ana P Luiz; Sonia Santana-Varela; Iain P Chessell; Fraser Welsh; John N Wood; Chantal Chenu
Journal:  Arthritis Rheumatol       Date:  2019-05-17       Impact factor: 10.995

4.  A Novel Rat Model to Study Postsurgical Pain After Joint Replacement Surgery.

Authors:  Naoki Aoyama; Masashi Izumi; Toru Morimoto; Hiroyuki Wada; Junpei Dan; Yusuke Kasai; Yoshinori Satake; Koji Aso; Masahiko Ikeuchi
Journal:  J Pain Res       Date:  2022-09-14       Impact factor: 2.832

Review 5.  Anti-nerve growth factor monoclonal antibodies for the control of pain in dogs and cats.

Authors:  Masataka Enomoto; Patrick W Mantyh; Joanna Murrell; John F Innes; B Duncan X Lascelles
Journal:  Vet Rec       Date:  2018-10-27       Impact factor: 2.695

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.